<DOC>
	<DOCNO>NCT00004441</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine optimum dose tauroursodeoxycholic acid ( TUDCA ) require achieve maximal bioavailability patient cystic fibrosis-associated liver disease . II . Compare optimized dos TUDCA ursodiol ( ursodeoxycholic acid ; UDCA ) effect biliary bile acid composition metabolism , serum biochemistry , fat absorption , fat-soluble vitamin status patient .</brief_summary>
	<brief_title>Study Tauroursodeoxycholic Acid Hepatobiliary Disease Cystic Fibrosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Objective I : This part study dose-response study determine optimal dose tauroursodeoxycholic acid ( TUDCA ) . Twenty-four patient randomize receive one three different dos TUDCA 3 month . Objective II : This part study double-blind crossover study compare optimize dos TUDCA optimize dos ursodiol 15 patient stratify accord age ( le 10 vs 10-20 v 20 year ) . Patients randomize receive either TUDCA ursodiol orally initial 3 month period , follow 3 month washout period drug administer . Patients receive alternate drug 3 month . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tauroursodeoxycholic acid</mesh_term>
	<mesh_term>Taurochenodeoxycholic Acid</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Cystic fibrosisassociated liver disease , define least one follow criterion : ( 1 ) Documented increase serum concentration liver enzymes ( least precede year ) ALT least twice normal AST least 1.5 time normal Alkaline phosphatase least 1.5 time normal GGT least 1.5 time normal ( 2 ) Persistent hepatomegaly 6 month duration define percuss liver span great 1 SEM age ( 3 ) Splenomegaly , define palpable spleen great 2.0 cm leave costal margin ( 4 ) Abnormalities ultrasound scan ( increased size , dishomogeneous echogenicity , nodular liver , irregular margin , splenomegaly ) within 6 month prior study entry Patients enrol first part study ( objective I ) eligible participate second part ( objective II ) Prior/Concurrent Therapy At least 3 month since prior ursodiol At least 3 month since treatment drug choleretic property effect influence bile acid metabolism Patient Characteristics Hepatic : No decompensated cirrhosis No hepatic neoplasm cholelithiasis Pulmonary : No significantly impaired pulmonary function FEV1 le 50 % Other : At least 15 kg body weight No severely compromise clinical nutritional state</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>